Syndax Pharmaceuticals's total assets for Q3 2024 were $425.81M, a decrease of -10.72% from the previous quarter. SNDX total liabilities were $59.38M for the fiscal quarter, a 39.36% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.